All In Biotech

Drug Trial Radar · NCT06265051

Tirofiban After Successful MT Recanalization in AIS

Safety and Efficacy of Adjunct Tirofiban Treatment After Successful Mechanical Thrombectomy Recanalization in Acute Anterior Circulation Ischemic Stroke- A Multicenter, Prospective, Double-blind, Randomized Trial

Last checked: Nov 20, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,380 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,380

Actual

Start

Apr 9, 2024

Primary completion

Dec 29, 2025

Study completion Dec 29, 2025

Sponsor

Lead sponsor
Xiang LuoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Fujian Medical University Union Hospital; Jingzhou Hospital Affiliated to Yangtze University; Xiangyang No 1 People's Hospital Affiliated to Hubei University of Medicine; Puren Hospital Affiliated to Wuhan University of Science and Technology; Zhongnan Hospital; First Affiliated Hospital of Fujian Medical University; Wuhan Central Hospital; Xianning Central Hospital; Shanxi Provincial People's Hospital; The Third People's Hospital of Hubei Province; Jingmen Central Hospital; Hubei University of Medicine; Wuhan No.1 Hospital; Nanyang Central Hospital; Yichang Central People's Hospital of China Three Gorges University; The Central Hospital of Huanggang; Zoucheng City People's Hospital; Qujing Central Hospital of Yunnan Province; Taihe Hospital, Affiliated Hospital of Hubei Province of Medicine; Second Affiliated Hospital of Soochow University; The First Affiliated Hospital of Nanchang University; Central Hospital of Xiaogan; The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture; Huangshi Central Hospital; Zigong No.1 Peoples Hospital; Xiangyang Hospital of Traditional Chinese Medicine; The First People's Hospital of Jingzhou; First People's Hospital of Xianyang; Jiujiang No.1 People's Hospital; Zhongxiang Hospital of Traditional Chinese Medicine; Jiangxi Provincial People's Hopital; The Lichuan ethnic Hospital of Traditional Chinese Medicine; Xiangyang Central Hospital People's Hospital of Huangpi District; Quanzhou First Hospital; Minda Hospital of Hubei Minzu University; The Cerebrovascular Hospital of Hubei Province; The First People's Hospital of Changde City; Longyan City First Hospital; Xiangzhou People's Hospital; Jingmen People's Hospital; The First People's Hospital of TianMen in Hubei Province; Hanyang Hospital Affiliated to Wuhan University of Science and Technology; Tongcheng People's Hospital; Gaoyou People's Hospital; Zaoyang First People's Hospital; CR & WISCO General Hospital; Wuhan Hankou Hospital; Lu'an People's Hospital of Anhui Hospital; Yingtan People's Hospital; Shiyan Renmin Hospital; Dali Bai Autonomous Prefecture People's Hospital; Three Gorges Hospital of Chongqing University; The Second People's Hospital of Jingzhou City; General Hospital of the Yangtze River Shipping; The Affiliated Hospital Of Southwest Medical University; Fujian Provincial Hospital; Zhongxiang People's Hospital; LiuZhou People's Hospital; The Fifth Hospital of Wuhan; Xiaogan First People's Hospital; Loudi Central Hospital; Ezhou Central Hospital; Second Xiangya Hospital of Central South University; Qingdao Central Hospital; Taizhou First People's Hospital; Renmin Hospital of Wuhan University; Hubei Provincial Hospital of Integrated Chinese & Western Medicine; The First Affiliated Hospital of BaoTou Medical College; Xianfeng People's Hospital; Wuhan Third Hospital; The Fourth Hospital of Wuhan; Chengdu Fifth People's Hospital; Xingyi People's Hospital; Affiliated Hospital of Shandong University of Traditional Chinese Medicine; Shenzhen Hospital of Southern Medical University; The Third People's Hospital of Jingzhou City; The First People's Hospital of Jiangxia District; Xihua First Hospital; Shanghai East Hospital
First posted
Feb 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute ischemic stroke with large vessel occlusion is a frequently occurring life-threatening condition. Although endovascular treatment can effectively open occluded vessels, the successful reperfusion rate exceeds 80%, but the rate of good prognosis is less than 50%. The current clinical focus is on how to improve futile recanalization. Tirofiban is widely used in the treatment of stroke, as it can effectively prevent vascular reocclusion and improve microcirculation perfusion. It has the potential to improve futile recanalization, but there is a lack of high-level evidence-based medical support. This multicenter, prospective, double-blind, randomized controlled trial was conducted to assess the effectiveness and safety of sequential tirofiban therapy following successful mechanical thrombectomy within 24 hours of onset.

Conditions

  • Acute Ischemic Stroke
  • Vessel Occlusion

Interventions

  • TirofibanDrug

    After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Tirofiban 5μg/kg was administered intravenously through the catheter artery at a rate of 1ml/min, followed by an intravenous infusion of 0.1μg/(kg·min) for 24 hours. Standard medical treatment was administered after the surgery.

  • Saline placeboDrug

    After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Saline placebo was administered in the same manner as tirofiban group. Standard medical treatment was administered after the surgery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients functionally independent (mRS score 0 to 2) at 90 daysTime frame: 90 days after randomization
  2. Number of participants with symptomatic intracranial hemorrhageTime frame: within 48 hours of randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.